HRTX HERON THERAPEUTICS, INC. /DE/
Nasdaq · SEC CIK 818033 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 177 since 2021-07-15, latest 2026-08-10 10:18
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Cusack Thomas | Dir | — | — |
| Hensley Mark Earl | COO | — | — |
| Morgan Adam | Dir | — | — |
| Rosen David Efraim | 10% | — | — |
| Dissanaike Sharmila | Dir | — | — |
| Kaseta Michael | Dir | — | — |
| Christian Waage | Dir | — | — |
| Duarte Ira | EVP, CFO | — | — |
| Johnson Craig A | Dir | — | — |
| Collard Craig A | CEO, Dir | — | — |
Transactions 216
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-17 | 2023-11-16 | HRTX | Duarte Ira | EVP, CFO | P - Purchase | $0.89 | +85.0K | 85.0K | New | +$75.7K | |
| 2023-11-17 | 2023-11-16 | HRTX | Collard Craig A | CEO, Dir | P - Purchase | $0.92 | +150.0K | 186.5K | +411% | +$138.0K | |
| DM | 2023-10-17 | 2023-07-25+ | HRTX | Peraza Lisa | VP, CAO | F - Tax | $1.47 | -15.6K | 53.2K | -23% | -$22.9K |
| DM | 2023-10-17 | 2023-07-25+ | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +45.1K | 55.7K | +427% | — |
| 2023-08-24 | 2023-08-22 | HRTX | Collard Craig A | CEO, Dir | F - Tax | $1.65 | -692 | 36.5K | -2% | -$1,142 | |
| DI | 2023-07-25 | 2023-07-21 | HRTX | Morgan Adam | Dir | P - Purchase | $1.37 | +2.49M | 6.99M | +55% | +$3.41M |
| D | 2023-07-17 | 2023-07-13 | HRTX | Szekeres David Leslie | EVP, COO | F - Tax | $1.31 | -2,012 | 33.8K | -6% | -$2,636 |
| DM | 2023-07-17 | 2023-07-13 | HRTX | Szekeres David Leslie | EVP, COO | M - OptEx | — | +5,814 | 35.8K | +19% | — |
| D | 2023-07-17 | 2023-07-13 | HRTX | Peraza Lisa | VP, CAO | F - Tax | $1.31 | -860 | 25.3K | -3% | -$1,127 |
| DM | 2023-07-17 | 2023-07-13 | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +2,485 | 26.2K | +10% | — |
| 2023-05-24 | 2023-05-22 | HRTX | Collard Craig A | CEO, Dir | F - Tax | $1.45 | -691 | 37.2K | -2% | -$1,002 | |
| D | 2023-04-17 | 2023-04-13 | HRTX | POYHONEN JOHN | Pres, CCO | F - Tax | $2.88 | -2,012 | 46.6K | -4% | -$5,795 |
| DM | 2023-04-17 | 2023-04-13 | HRTX | POYHONEN JOHN | Pres, CCO | M - OptEx | — | +5,814 | 48.7K | +14% | — |
| D | 2023-04-17 | 2023-04-13 | HRTX | Peraza Lisa | VP, CAO | F - Tax | $2.88 | -860 | 23.7K | -4% | -$2,477 |
| DM | 2023-04-17 | 2023-04-13 | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +2,484 | 22.6K | +12% | — |
| DM | 2023-04-17 | 2023-04-13 | HRTX | Szekeres David Leslie | EVP, COO | M - OptEx | — | +5,814 | 27.4K | +27% | — |
| D | 2023-04-17 | 2023-04-13 | HRTX | Szekeres David Leslie | EVP, COO | F - Tax | $2.88 | -2,012 | 30.0K | -6% | -$5,795 |
| DM | 2023-04-17 | 2023-04-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development | M - OptEx | — | +5,814 | 29.7K | +24% | — |
| D | 2023-04-17 | 2023-04-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development | F - Tax | $2.88 | -1,417 | 28.3K | -5% | -$4,081 |
| D | 2023-02-24 | 2023-02-22 | HRTX | Morgan Adam | Dir, See Notes 2, 3 | A - Grant | $0.00 | +37.9K | 37.9K | New | $0 |
| DM | 2023-01-17 | 2023-01-13 | HRTX | POYHONEN JOHN | Pres, CCO | M - OptEx | — | +5,814 | 44.9K | +15% | — |
| D | 2023-01-17 | 2023-01-13 | HRTX | POYHONEN JOHN | Pres, CCO | F - Tax | $3.17 | -2,012 | 42.8K | -4% | -$6,378 |
| D | 2023-01-17 | 2023-01-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $3.17 | -2,012 | 23.9K | -8% | -$6,378 |
| DM | 2023-01-17 | 2023-01-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 25.9K | +29% | — |
| D | 2023-01-17 | 2022-10-31 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | J - Other | $3.27 | +1,655 | 20.1K | +9% | +$5,412 |
| DM | 2023-01-17 | 2023-01-13 | HRTX | Quart Barry D | CEO, Dir | M - OptEx | — | +19.8K | 183.2K | +12% | — |
| D | 2023-01-17 | 2022-10-31 | HRTX | Quart Barry D | CEO, Dir | J - Other | $3.27 | +1,655 | 163.4K | +1% | +$5,412 |
| D | 2023-01-17 | 2023-01-13 | HRTX | Quart Barry D | CEO, Dir | F - Tax | $3.17 | -5,219 | 178.0K | -3% | -$16.5K |
| D | 2023-01-17 | 2023-01-13 | HRTX | Szekeres David Leslie | EVP, COO | F - Tax | $3.17 | -2,012 | 26.1K | -7% | -$6,378 |
| D | 2023-01-17 | 2022-10-31 | HRTX | Szekeres David Leslie | EVP, COO | J - Other | $3.27 | +1,654 | 22.3K | +8% | +$5,409 |
| DM | 2023-01-17 | 2023-01-13 | HRTX | Szekeres David Leslie | EVP, COO | M - OptEx | — | +5,814 | 28.2K | +26% | — |
| D | 2023-01-17 | 2023-01-13 | HRTX | Peraza Lisa | VP, CAO | F - Tax | $3.17 | -1,013 | 22.1K | -4% | -$3,211 |
| DM | 2023-01-17 | 2023-01-13 | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +2,485 | 21.1K | +13% | — |
| D | 2022-12-20 | 2022-12-16 | HRTX | Johnson Craig A | Dir | A - Grant | $0.00 | +38.6K | 51.9K | +290% | $0 |
| D | 2022-12-20 | 2022-12-16 | HRTX | Dissanaike Sharmila | Dir | A - Grant | $0.00 | +38.6K | 55.3K | +231% | $0 |
| D | 2022-12-20 | 2022-12-16 | HRTX | Rodriguez Susan | Dir | A - Grant | $0.00 | +38.6K | 55.3K | +231% | $0 |
| D | 2022-12-20 | 2022-12-16 | HRTX | Christian Waage | Dir | A - Grant | $0.00 | +38.6K | 52.2K | +283% | $0 |
| D | 2022-12-20 | 2022-12-16 | HRTX | DAVIS STEPHEN | Dir | A - Grant | $0.00 | +38.6K | 52.0K | +287% | $0 |
| DM | 2022-10-17 | 2022-10-13 | HRTX | Quart Barry D | CEO, Dir | M - OptEx | — | +19.8K | 167.0K | +13% | — |
| D | 2022-10-17 | 2022-10-13 | HRTX | Quart Barry D | CEO, Dir | F - Tax | $3.76 | -5,219 | 161.8K | -3% | -$19.6K |
| D | 2022-10-17 | 2022-10-13 | HRTX | Peraza Lisa | VP, CAO | F - Tax | $3.76 | -861 | 20.6K | -4% | -$3,237 |
| DM | 2022-10-17 | 2022-10-13 | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +2,485 | 21.4K | +13% | — |
| DM | 2022-10-17 | 2022-10-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 20.5K | +40% | — |
| D | 2022-10-17 | 2022-10-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $3.76 | -2,012 | 18.5K | -10% | -$7,565 |
| DM | 2022-10-17 | 2022-10-13 | HRTX | POYHONEN JOHN | Pres, CCO | M - OptEx | — | +5,814 | 41.1K | +16% | — |
| D | 2022-10-17 | 2022-10-13 | HRTX | POYHONEN JOHN | Pres, CCO | F - Tax | $3.76 | -2,012 | 39.0K | -5% | -$7,565 |
| D | 2022-10-17 | 2022-10-13 | HRTX | Szekeres David Leslie | EVP, COO | F - Tax | $3.76 | -2,012 | 20.7K | -9% | -$7,565 |
| DM | 2022-10-17 | 2022-10-13 | HRTX | Szekeres David Leslie | EVP, COO | M - OptEx | — | +5,814 | 22.7K | +34% | — |
| D | 2022-07-15 | 2022-07-13 | HRTX | Szekeres David Leslie | EVP, COO | F - Tax | $3.01 | -2,012 | 16.9K | -11% | -$6,056 |
| DM | 2022-07-15 | 2022-07-13 | HRTX | Szekeres David Leslie | EVP, COO | M - OptEx | — | +5,814 | 14.3K | +68% | — |
| D | 2022-07-15 | 2022-04-29 | HRTX | Szekeres David Leslie | EVP, COO | J - Other | $3.84 | +1,505 | 13.1K | +13% | +$5,779 |
| D | 2022-07-15 | 2022-07-13 | HRTX | Quart Barry D | CEO, Dir | F - Tax | $3.01 | -5,219 | 147.2K | -3% | -$15.7K |
| DM | 2022-07-15 | 2022-07-13 | HRTX | Quart Barry D | CEO, Dir | M - OptEx | — | +19.8K | 152.5K | +15% | — |
| D | 2022-07-15 | 2022-04-29 | HRTX | Quart Barry D | CEO, Dir | J - Other | $3.84 | +1,504 | 132.7K | +1% | +$5,775 |
| DM | 2022-07-15 | 2022-07-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 16.7K | +53% | — |
| D | 2022-07-15 | 2022-07-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $3.01 | -2,012 | 14.7K | -12% | -$6,056 |
| D | 2022-07-15 | 2022-07-13 | HRTX | POYHONEN JOHN | Pres, CCO | F - Tax | $3.01 | -2,012 | 35.2K | -5% | -$6,056 |
| DM | 2022-07-15 | 2022-07-13 | HRTX | POYHONEN JOHN | Pres, CCO | M - OptEx | — | +5,814 | 37.3K | +18% | — |
| DM | 2022-07-15 | 2022-07-13 | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +2,485 | 19.8K | +14% | — |
| D | 2022-07-15 | 2022-07-13 | HRTX | Peraza Lisa | VP, CAO | F - Tax | $3.01 | -860 | 19.0K | -4% | -$2,589 |
| 2022-05-04 | 2022-05-03 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | S - Sale | $4.76 | -1,504 | 10.9K | -12% | -$7,159 | |
| 2022-05-04 | 2022-04-29 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | J - Other | $3.84 | +1,504 | 12.4K | +14% | +$5,775 | |
| DM | 2022-04-15 | 2022-04-13 | HRTX | POYHONEN JOHN | Pres, CCO | M - OptEx | — | +5,814 | 28.9K | +25% | — |
| D | 2022-04-15 | 2022-04-13 | HRTX | POYHONEN JOHN | Pres, CCO | F - Tax | $6.07 | -2,012 | 31.4K | -6% | -$12.2K |
| DM | 2022-04-15 | 2022-04-13 | HRTX | Quart Barry D | CEO, Dir | M - OptEx | — | +19.8K | 136.4K | +17% | — |
| D | 2022-04-15 | 2022-04-13 | HRTX | Quart Barry D | CEO, Dir | F - Tax | $6.07 | -5,219 | 131.2K | -4% | -$31.7K |
| DM | 2022-04-15 | 2022-04-13 | HRTX | Szekeres David Leslie | EVP, COO | M - OptEx | — | +5,814 | 9,033 | +181% | — |
| D | 2022-04-15 | 2022-04-13 | HRTX | Szekeres David Leslie | EVP, COO | F - Tax | $6.07 | -2,012 | 11.6K | -15% | -$12.2K |
| DM | 2022-04-15 | 2022-04-13 | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +2,484 | 18.2K | +16% | — |
| D | 2022-04-15 | 2022-04-13 | HRTX | Peraza Lisa | VP, CAO | F - Tax | $6.07 | -860 | 17.3K | -5% | -$5,220 |
| DM | 2022-04-15 | 2022-04-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 8,320 | +232% | — |
| D | 2022-04-15 | 2022-04-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $6.07 | -2,012 | 10.9K | -16% | -$12.2K |
| D | 2022-01-14 | 2022-01-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $8.30 | -2,012 | 7,070 | -22% | -$16.7K |
| DM | 2022-01-14 | 2022-01-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +5,814 | 4,518 | New | — |
| DM | 2022-01-14 | 2022-01-13 | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +2,485 | 14.7K | +20% | — |
| D | 2022-01-14 | 2022-01-13 | HRTX | Peraza Lisa | VP, CAO | F - Tax | $8.30 | -966 | 15.7K | -6% | -$8,018 |
| D | 2022-01-14 | 2022-01-13 | HRTX | Szekeres David Leslie | EVP, COO | F - Tax | $8.30 | -2,012 | 7,783 | -21% | -$16.7K |
| DM | 2022-01-14 | 2022-01-13 | HRTX | Szekeres David Leslie | EVP, COO | M - OptEx | — | +5,814 | 5,231 | New | — |
| DM | 2022-01-14 | 2022-01-13 | HRTX | POYHONEN JOHN | Pres, CCO | M - OptEx | — | +5,814 | 25.1K | +30% | — |
| D | 2022-01-14 | 2022-01-13 | HRTX | POYHONEN JOHN | Pres, CCO | F - Tax | $8.30 | -2,012 | 27.6K | -7% | -$16.7K |
| DM | 2022-01-14 | 2022-01-13 | HRTX | Quart Barry D | CEO, Dir | M - OptEx | — | +19.8K | 121.9K | +19% | — |
| D | 2022-01-14 | 2022-01-13 | HRTX | Quart Barry D | CEO, Dir | F - Tax | $8.30 | -5,219 | 116.6K | -4% | -$43.3K |
| D | 2021-12-23 | 2021-12-22 | HRTX | Rodriguez Susan | Dir | A - Grant | $0.00 | +10.5K | 16.7K | +167% | $0 |
| D | 2021-12-23 | 2021-12-22 | HRTX | Christian Waage | Dir | A - Grant | $0.00 | +10.5K | 13.7K | +327% | $0 |
| D | 2021-12-23 | 2021-12-21 | HRTX | Christian Waage | Dir | S - Sale | $9.73 | -300 | 3,200 | -9% | -$2,919 |
| 2021-12-23 | 2021-10-29 | HRTX | POYHONEN JOHN | Pres, CCO | J - Other | $9.36 | +817 | 23.8K | +4% | +$7,647 | |
| D | 2021-12-23 | 2021-12-22 | HRTX | Dissanaike Sharmila | Dir | A - Grant | $0.00 | +10.5K | 16.7K | +167% | $0 |
| D | 2021-12-23 | 2021-12-22 | HRTX | DAVIS STEPHEN | Dir | A - Grant | $0.00 | +10.5K | 13.5K | +348% | $0 |
| D | 2021-12-23 | 2021-12-21 | HRTX | Johnson Craig A | Dir | S - Sale | $9.73 | -250 | 2,840 | -8% | -$2,432 |
| D | 2021-12-23 | 2021-12-22 | HRTX | Johnson Craig A | Dir | A - Grant | $0.00 | +10.5K | 13.3K | +368% | $0 |
| D | 2021-10-15 | 2021-10-13 | HRTX | POYHONEN JOHN | Pres, CCO | F - Tax | $10.55 | -433 | 23.0K | -2% | -$4,568 |
| D | 2021-10-15 | 2021-10-13 | HRTX | POYHONEN JOHN | Pres, CCO | M - OptEx | — | +1,250 | 23.5K | +6% | — |
| D | 2021-10-15 | 2021-10-13 | HRTX | Szekeres David Leslie | EVP, COO | M - OptEx | — | +1,250 | 4,414 | +40% | — |
| D | 2021-10-15 | 2021-10-13 | HRTX | Szekeres David Leslie | EVP, COO | F - Tax | $10.55 | -433 | 3,981 | -10% | -$4,568 |
| D | 2021-10-15 | 2021-10-13 | HRTX | Peraza Lisa | VP, CAO | F - Tax | $10.55 | -191 | 14.2K | -1% | -$2,015 |
| D | 2021-10-15 | 2021-10-13 | HRTX | Peraza Lisa | VP, CAO | M - OptEx | — | +552 | 14.4K | +4% | — |
| D | 2021-10-15 | 2021-10-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | M - OptEx | — | +1,250 | 3,701 | +51% | — |
| D | 2021-10-15 | 2021-10-13 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | F - Tax | $10.55 | -433 | 3,268 | -12% | -$4,568 |
| D | 2021-10-15 | 2021-10-13 | HRTX | Quart Barry D | CEO, Dir | M - OptEx | — | +3,646 | 103.0K | +4% | — |
| D | 2021-10-15 | 2021-10-13 | HRTX | Quart Barry D | CEO, Dir | F - Tax | $10.55 | -963 | 102.1K | -0.9% | -$10.2K |
Purchase Sale Sale after option exercise All abbreviations